Search Results

Cimeio Therapeutics today announced a preclinical research collaboration with Saar Gill, M.D., Ph.D., an associate professor of medicine and a researcher in the Center for Cellular Immunotherapies in the Perelman School of Medicine at the University of Pennsylvania, to research and evaluate a novel universal immunotherapy with potential to treat multiple blood and bone marrow cancers.

Verismo Therapeutics , a clinical-stage CAR T company, Penn spinout, and pioneer of the novel KIR-CAR platform technology, today announced that it had entered into a licensing agreement with the University of Pennsylvania.

Researchers at Children’s Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania revealed a powerful new bone marrow atlas that will offer the public a first-of-its-kind visual passport into the spectrum of healthy and diseased blood production.

Verismo Therapeutics, a clinical-stage CAR-T company and University of Pennsylvania spinout developing novel KIR-CAR platform technology, today announced that it has activated its STAR-101 Phase 1 clinical trial at the University of Pennsylvania.

RVAC Medicines (US), Inc. today announced the collaboration under a Sponsored Research Agreement with the University of Pennsylvania (“Penn”) focused on the discovery and development of mRNA vaccines that can modulate the body’s normal immune response as possible treatments for certain autoimmune diseases and allergic conditions.

Danaher Corporation (NYSE: DHR), a global science and technology innovator, today announced a strategic partnership with the University of Pennsylvania (Penn) focusing on cell therapy innovation.

Astellas is opening a second location of Universal Cells, its wholly owned subsidiary, at a research campus in Japan and transferring 12 roles from Universal’s Seattle location.

Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.